What Challenges Exist in Targeting the ALT Pathway?
Despite its potential, targeting the ALT pathway faces several challenges. One major hurdle is the heterogeneity of ALT mechanisms among different cancer types, which complicates the development of a one-size-fits-all treatment. Additionally, the lack of specific biomarkers for ALT activity makes it difficult to identify patients who would benefit from ALT-targeted therapies. Moreover, since the ALT pathway shares many components with normal DNA repair processes, there is a risk of off-target effects that could harm normal cells.
